Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Artificial sweeteners might trigger diabetes
World Alzheimer’s Report Suggests Dementia Can Be Preventable
Artificial spleen can rid the body of infections
Obese can lean down through social networking sites: Study
China Plans to Add Stimulus to Boost Economy
Stocks of Sears Drop to 52 Week Low as its CEO Offers Loan of $400 million
Link established between baldness, prostate cancer
Cervical cancer can be checked through urine test
Legalisation of medical cannabis gets Tony Abbott’s support
Risk of heart disease can be increased by working for longer hours
Australian goldfish is recovering ‘swimmingly well’ following surgery
5:2 diet again in limelight